公开(公告)号：US20240382580A1

公开(公告)日：2024-11-21

申请号：US18686564

申请日：2022-08-26

Applicant: CORNELL UNIVERSITY

Inventor： Hector AGUILAR-CARRENO

IPC: A61K39/205 ,  A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K39/155 ,  A61K39/215 ,  A61K39/275 ,  C12N7/00

Abstract: The present disclosure is directed to Compositions comprising a population of multivalent viral particles are described herein. Also described herein are immunogenic compositions comprising a population of multivalent viral particles. Additionally, methods of making a multivalent immunogenic composition comprising a population of multivalent viral particles are described. Lastly, methods of using an immunogenic composition to elicit an immune response in a subject are described herein.

公开(公告)号：US12060420B2

公开(公告)日：2024-08-13

申请号：US17205251

申请日：2021-03-18

Applicant: Stichting Sanquin Bloedvoorziening

Inventor： Timo Kars Van Den Berg

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/12 ,  A61K39/275 ,  A61K39/395 ,  C07K16/30 ,  C07K16/32

CPC classification number: C07K16/2803 ,  A61K39/12 ,  A61K39/275 ,  A61K39/395 ,  A61K39/3955 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/2893 ,  C07K16/30 ,  C07K16/32 ,  A61K2039/507 ,  A61K2039/57 ,  A61K2039/572 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/77 ,  C12N2710/24034 ,  C12N2710/24134

Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.

公开(公告)号：US20240091338A1

公开(公告)日：2024-03-21

申请号：US18115556

申请日：2023-02-28

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Alfredo Nicosia ,  Ricardo Cortese ,  Alessandra Vitelli

IPC: A61K39/155 ,  A61K39/12 ,  A61K39/235 ,  A61K39/275

CPC classification number: A61K39/155 ,  A61K39/12 ,  A61K39/235 ,  A61K39/275 ,  A61K2039/545

Abstract: The present invention relates to administration regimens which are particularly suited for vaccine composition comprising polynucleotides which encode immunogenic polypeptides. Said administration regimens involve the repeated administration of a vaccine composition and enhance the immune response against the immunogenic polypeptide.

公开(公告)号：US11890270B2

公开(公告)日：2024-02-06

申请号：US17136674

申请日：2020-12-29

Applicant: Siga Technologies, Inc.

Inventor： Shanthakumar R. Tyavanagimatt ,  Melialani A. C. L. S. Anderson ,  William C. Weimers ,  Dylan Nelson ,  Tove' C. Bolken ,  Dennis E. Hruby ,  Michael H. O'Neill ,  Gary Sweetapple ,  Kelley A. McCloughan

IPC: A61K31/404 ,  A61K39/275 ,  C07D209/76 ,  A61K9/16 ,  A61K9/48 ,  C07D209/70

CPC classification number: A61K31/404 ,  A61K9/1652 ,  A61K9/4866 ,  A61K39/275 ,  C07D209/70 ,  C07D209/76

Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

公开(公告)号：US11844832B2

公开(公告)日：2023-12-19

申请号：US16994500

申请日：2020-08-14

Applicant: Najít Technologies, Inc.

Inventor： Ian J. Amanna ,  Elizabeth A. Poore

IPC: A61K39/12 ,  C12N7/00 ,  A61P31/14 ,  A61K39/145 ,  A61K39/02 ,  A61K33/40 ,  A61P31/16 ,  A61K39/112 ,  A61K39/275 ,  A61K39/00

CPC classification number: A61K39/145 ,  A61K33/40 ,  A61K39/02 ,  A61K39/0283 ,  A61K39/105 ,  A61K39/12 ,  A61K39/275 ,  A61P31/14 ,  A61P31/16 ,  C12N7/00 ,  A61K2039/521 ,  A61K2039/5252 ,  C12N2760/16131 ,  C12N2760/16134 ,  C12N2760/16163 ,  C12N2760/16171 ,  C12N2770/24134 ,  C12N2770/24163 ,  C12N2770/24171 ,  C12N2770/36134 ,  C12N2770/36163 ,  C12N2770/36171 ,  Y02A50/30

Abstract: Provided are methods for rapidly inactivating a pathogen, or for producing a vaccine composition containing an inactivated noninfectious pathogen having retained antigenicity and/or immunogenicity, comprising exposing the pathogen to a chemical inactivating agent (e.g., one or more chemical oxidizing, alkylating or crosslinking agents) in the presence of inorganic polyatomic oxyanions in an amount and for a time sufficient to render the pathogen noninfectious while enhancing retention of pathogen antigenicity and/or immunogenicity relative to that retained by contacting the pathogen with the chemical inactivating agent alone. The methods are broadly applicable to pathogens having RNA or DNA genomes (e.g., including viruses, bacteria, fungi, and parasites). Also provided are vaccine compositions (medicaments) containing a pathogen inactivated by exposure to an inactivating agent in the presence of elevated concentrations of inorganic polyatomic oxyanions, and methods for eliciting an immune response in a subject by administering the vaccine compositions.

公开(公告)号：US20230338516A1

公开(公告)日：2023-10-26

申请号：US18005291

申请日：2021-08-16

Applicant: PRIME VECTOR TECHNOLOGIES GMBH

Inventor： Melanie MUELLER ,  Ralf AMANN

IPC: A61K39/275 ,  C12N15/86 ,  C07K14/705

CPC classification number: A61K39/275 ,  C07K14/70532 ,  C07K14/70575 ,  C12N15/86 ,  A61K2039/5256

Abstract: The present invention relates to a recombinant Poxviridae vector expressing a co-stimulatory molecule, a cell containing the recombinant Poxviridae vector, a pharmaceutical composition containing the recombinant Poxviridae vector according to the invention and/or the cell according to the invention, and a method for the treatment of a living being in need of a vaccination with an antigen.

公开(公告)号：US20230009041A1

公开(公告)日：2023-01-12

申请号：US17732141

申请日：2022-04-28

Applicant: Arizona Board of Regents, a body corporate of the State of Arizona acting for and on behalf of ,  Consejo Superior De Investigaciones Cientificas ,  IPPOX Foundation

Inventor： Giuseppe Pantaleo ,  Thierry Calandra ,  Alexandre Harari ,  Thierry Roger ,  Mariano Esteban ,  Bertram Jacobs ,  Karen Kibler ,  Cornelius Melief ,  Rafick-Pierre Sekaly ,  Elias Haddad ,  James Tartaglia

IPC: C12N15/86 ,  A61K39/275 ,  A61K39/295

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

公开(公告)号：US20230002741A1

公开(公告)日：2023-01-05

申请号：US17827320

申请日：2022-05-27

Applicant: TONIX PHARMACEUTICALS HOLDING CORP. ,  TONIX PHARMA LIMITED

Inventor： David Evans ,  Ryan Noyce ,  Seth Lederman

IPC: C12N7/00 ,  A61K39/275 ,  A61K39/12 ,  A61P31/20

Abstract: The invention relates, in general, to synthetic chimeric poxviruses, compositions comprising such viruses, and the development and use of systems and methods for producing such synthetic chimeric poxviruses. The synthetic chimeric poxviruses are well suited for live virus vaccines and pharmaceutical formulations.

公开(公告)号：US20220241421A1

公开(公告)日：2022-08-04

申请号：US17580896

申请日：2022-01-21

Applicant: Abic Biological Laboratories Ltd.

Inventor： Noel Yves Henri Jean Genin

IPC: A61K47/26 ,  A61K9/46 ,  A61K39/12 ,  A61K9/20 ,  A61K39/00 ,  A61K39/255 ,  A61K39/275 ,  A61K9/00 ,  A61K39/17 ,  A61K39/215

Abstract: The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

公开(公告)号：US11345928B2

公开(公告)日：2022-05-31

申请号：US16513757

申请日：2019-07-17

Applicant: Arizona Board of Regents ,  Consejo Superior De Investigaciones Cientificas ,  IPPOX Foundation

Inventor： Giuseppe Pantaleo ,  Thierry Calandra ,  Alexandre Harari ,  Thierry Roger ,  Mariano Esteban ,  Bertram Jacobs ,  Karen Kibler ,  Cornelius Melief ,  Rafick-Pierre Sekaly ,  Elias El Haddad ,  James Tartaglia

IPC: C12N15/86 ,  A61K39/12 ,  A61K39/275 ,  A61K39/295 ,  A61K49/00 ,  A61K39/00

Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.